Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexcom’s G7 Expands Globally After A Long Wait

Executive Summary

Dexcom has expanded the availability of its G7 sensor to five new markets, including the UK and Germany. FDA approval in the US has been delayed by software changes.

You may also be interested in...



News We’re Watching: Dexcom Expands In Ireland; Neurostim Updates From NANS; Novel Nanoparticles Treat Cancer In Mice; And More

Medtech Insight's News We're Watching highlights medtech industry and R&D developments that you may have missed over the last few weeks. This update covers some late-breaking results announced at the North American Neuromodulation Society (NANS) annual meeting in Las Vegas, as well as an update on Dexcom's new facility in Ireland, and a promising mouse experiment with nanoparticles that kill cancer cells.

Digital Health Roundup: Telehealth Strong, Diabetes Recalls And Expansions, AI And Radiology

In this month’s Digital Health Roundup, Medtech Insight’s Reed Miller offers a recap from the recent TCT 2022 meeting and talks about Butterfly Network’s expansion into Africa while Marion Webb highlights her interview with Aidoc’s CEO Elad Walach discussing plans for the AI-based software company.

FDA Clears Abbott’s Libre 3

Abbott’s FreeStyle Libre 3 system will soon be available in the US. It is 70% smaller than the Libre 2 while also providing better accuracy.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel